Sintx Technologies, Inc. (SINT)

NCM – Цена в реальном времени. Валюта: USD

1.92

+0.07 (3.78%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.90

-0.02 (-1.04%)

После закрытия: Jun 26, 2026, 5:37 PM EDT

03.06.2026

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SALT LAKE CITY, Utah, June 03, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today announced that it has entered into securities purchase agreements with institutional and accredited investors pursuant to which the Company agreed to issue and sell an aggregate of 1,882,845 shares of common stock in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors (i) Class A Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock and (ii) Class B Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock.

17.05.2026

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

Salt Lake City, Utah--(Newsfile Corp. - May 17, 2026) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a medical technology company focused on advanced ceramics and silicon nitride biomaterials, today announced that management will present at the LD Micro Invitational XVI Conference in Los Angeles, California, at the Luxe Sunset Blvd Hotel. During the presentation, management expects to discuss recent progress in commercialization, product development, and manufacturing initiatives supporting the Company's silicon nitride biomaterials platform, including applications in orthopedics, spine, foot and ankle, and patient-specific implant markets.

23.03.2026

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026

19.03.2026

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform

18.02.2026

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

Appointment supports acceleration of revenue opportunities from SiNERGY ™ silicon nitride devices and antipathogenic fibrous material technologies

29.01.2026

SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026.

01.12.2025

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation (“EVONIK”), a global leader in high‑performance polymers, to manufacture the Company's proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for AI‑assisted additive manufacturing of patient‑specific implants that will be produced using equipment already in place at SINTX's U.S.-based production facility.

Видео

No Data

There is no data to display

Пресс-релизы

03.06.2026

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

23.03.2026

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026

19.03.2026

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform

18.02.2026

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

Appointment supports acceleration of revenue opportunities from SiNERGY ™ silicon nitride devices and antipathogenic fibrous material technologies

Sintx Technologies, Inc. (SINT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Sintx Technologies, Inc. (SINT)

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Видео

No Data

Пресс-релизы

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Видео

No Data

Пресс-релизы

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

Search stocks

Sintx Technologies, Inc. (SINT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Sintx Technologies, Inc. (SINT)

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Видео

No Data

Пресс-релизы

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Видео

No Data

Пресс-релизы

SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms